INmune Bio Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	Current	2023	2022	2021	2020	2019	2018	2017	2016
Market Capitalization	193	203	114	182	232	62	-	-	-
Market Cap Growth	-	78.35%	-37.49%	-21.41%	270.69%	-	-	-	-
Enterprise Value	168	178	77	122	210	56	-0	-1	0
PE Ratio	-6.76	-6.76	-4.17	-6.00	-19.14	-8.14	-	-	-
PS Ratio	1247.23	1309.19	304.22	1005.53	21052.15	-	-	-	-
PB Ratio	5.18	5.44	1.89	2.27	5.98	2.65	-	-	-
P/FCF Ratio	-16.94	-16.94	-5.02	-6.39	-25.89	-11.60	-	-	-
P/OCF Ratio	-16.94	-16.94	-5.02	-6.39	-25.89	-11.60	-	-	-
EV/Sales Ratio	1083.28	1145.25	205.71	676.39	19069.70	-	-	-	-
EV/EBITDA Ratio	-5.92	-5.92	-2.82	-4.04	-17.34	-7.25	0.01	1.65	-0.75
EV/EBIT Ratio	-5.92	-5.92	-2.82	-4.04	-17.34	-7.25	0.01	1.65	-0.75
EV/FCF Ratio	-14.82	-14.82	-3.39	-4.30	-23.46	-10.33	0.09	1.80	-0.66
Debt / Equity Ratio	0.28	0.28	0.25	0.19	0.00	0.01	-	-	-2.35
Debt / EBITDA Ratio	-0.35	-0.35	-0.56	-0.50	-0.01	-0.02	-	-	-1.26
Debt / FCF Ratio	-0.87	-0.87	-0.67	-0.53	-0.02	-0.03	-	-	-1.10
Quick Ratio	1.94	1.94	4.78	17.16	12.37	9.99	0.25	4.78	0.50
Current Ratio	2.16	2.16	5.92	18.95	13.51	11.09	1.03	6.13	0.75
Asset Turnover	0.00	0.00	0.00	0.00	0	0	0	0	-
Return on Equity (ROE)	-64.10%	-64.10%	-40.50%	-44.10%	-39.00%	-31.30%	-71.80%	-9.30%	-
Return on Assets (ROA)	-45.60%	-45.60%	-31.40%	-36.30%	-37.20%	-30.40%	-69.50%	-8.80%	-
Return on Capital (ROIC)	-62.81%	-62.81%	-36.20%	-31.78%	-31.42%	-32.62%	-75.21%	-5.42%	-113.29%
Earnings Yield	-15.52%	-14.79%	-23.99%	-16.67%	-5.22%	-12.29%	-	-	-
FCF Yield	-6.20%	-5.90%	-19.94%	-15.66%	-3.86%	-8.62%	-	-	-
Buyback Yield / Dilution	-0.30%	-0.30%	-11.14%	-34.55%	-16.70%	-18.39%	-32.18%	-31.28%	-
Total Shareholder Return	-0.30%	-0.30%	-11.14%	-34.55%	-16.70%	-18.39%	-32.18%	-31.28%	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).